Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| B cell | 26 studies | 27% ± 9% | |
| memory B cell | 16 studies | 24% ± 7% | |
| naive B cell | 15 studies | 29% ± 8% | |
| conventional dendritic cell | 6 studies | 20% ± 4% | |
| plasma cell | 3 studies | 26% ± 4% | |
| germinal center B cell | 3 studies | 28% ± 5% | |
| dendritic cell | 3 studies | 28% ± 11% |
Insufficient scRNA-seq data for expression of HLA-DOB at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 99% | 306.11 | 571 / 578 | 93% | 6.85 | 1076 / 1155 |
| breast | 92% | 160.42 | 422 / 459 | 76% | 4.46 | 854 / 1118 |
| thymus | 72% | 179.94 | 473 / 653 | 84% | 5.50 | 506 / 605 |
| uterus | 72% | 77.45 | 122 / 170 | 81% | 4.77 | 373 / 459 |
| skin | 87% | 150.93 | 1575 / 1809 | 65% | 4.35 | 309 / 472 |
| kidney | 78% | 125.78 | 69 / 89 | 73% | 3.91 | 656 / 901 |
| bladder | 81% | 146.86 | 17 / 21 | 68% | 3.12 | 345 / 504 |
| intestine | 83% | 465.86 | 798 / 966 | 64% | 2.67 | 338 / 527 |
| esophagus | 69% | 101.32 | 1004 / 1445 | 77% | 2.84 | 141 / 183 |
| stomach | 79% | 121.69 | 284 / 359 | 66% | 2.79 | 189 / 286 |
| ovary | 59% | 84.10 | 107 / 180 | 82% | 3.48 | 353 / 430 |
| prostate | 78% | 122.97 | 190 / 245 | 42% | 1.04 | 212 / 502 |
| liver | 55% | 46.35 | 124 / 226 | 50% | 2.48 | 202 / 406 |
| brain | 60% | 62.33 | 1577 / 2642 | 43% | 1.23 | 304 / 705 |
| pancreas | 16% | 12.79 | 54 / 328 | 85% | 5.77 | 152 / 178 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 97.95 | 29 / 29 |
| spleen | 100% | 3082.05 | 241 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 98% | 915.44 | 913 / 929 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 91% | 8.37 | 41 / 45 |
| adipose | 85% | 114.70 | 1026 / 1204 | 0% | 0 | 0 / 0 |
| adrenal gland | 62% | 70.10 | 159 / 258 | 16% | 0.30 | 37 / 230 |
| blood vessel | 59% | 68.48 | 792 / 1335 | 0% | 0 | 0 / 0 |
| heart | 34% | 28.53 | 296 / 861 | 0% | 0 | 0 / 0 |
| muscle | 15% | 9.91 | 120 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 13% | 0.41 | 10 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0019886 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class II |
| GO_0002250 | Biological process | adaptive immune response |
| GO_0050870 | Biological process | positive regulation of T cell activation |
| GO_0050778 | Biological process | positive regulation of immune response |
| GO_0002587 | Biological process | negative regulation of antigen processing and presentation of peptide antigen via MHC class II |
| GO_0002503 | Biological process | peptide antigen assembly with MHC class II protein complex |
| GO_0005764 | Cellular component | lysosome |
| GO_0031902 | Cellular component | late endosome membrane |
| GO_0042613 | Cellular component | MHC class II protein complex |
| GO_0005765 | Cellular component | lysosomal membrane |
| GO_0023026 | Molecular function | MHC class II protein complex binding |
| GO_0032395 | Molecular function | MHC class II receptor activity |
| GO_0042605 | Molecular function | peptide antigen binding |
| Gene name | HLA-DOB |
| Protein name | HLA class II histocompatibility antigen, DO beta chain HLA-DOB (MHC class II antigen) (Major histocompatibility complex, class II, DO beta, isoform CRA_a) HLA-DOB (MHC class II antigen) HLA-DOB protein Major histocompatibility complex, class II, DO beta, isoform CRA_b (cDNA FLJ55403, highly similar to HLA class II histocompatibility antigen, DObeta chain) (cDNA, FLJ79096, highly similar to HLA class II histocompatibility antigen, DObeta chain) Major histocompatibility complex, class II, DO beta HLA class II histocompatibility antigen, DO beta chain (Major histocompatibility complex, class II, DO beta) HLA class II histocompatibility antigen, DO beta chain (MHC class II antigen DOB) |
| Synonyms | HLA_DOB hCG_2039124 |
| Description | FUNCTION: Important modulator in the HLA class II restricted antigen presentation pathway by interaction with the HLA-DM molecule in B-cells. Modifies peptide exchange activity of HLA-DM. |
| Accessions | A0A140T945 ENST00000527042.1 ENST00000472450.5 P13765 ENST00000477041.5 ENST00000463161.5 ENST00000474604.5 ENST00000454286.6 A0A140T9F2 X5CF66 ENST00000488325.5 X5D174 ENST00000455155.5 A0A140T9Z3 Q5QNS2 H0Y4X4 ENST00000453971.1 ENST00000454969.6 A0A140T935 ENST00000448690.1 A0A140TA22 ENST00000426644.6 ENST00000438763.7 E9PI00 ENST00000439310.1 B7Z742 A0A140T9U5 ENST00000456406.6 ENST00000447178.6 ENST00000447394.1 ENST00000465683.5 ENST00000413252.1 A0A140T9L2 Q6FHE3 ENST00000648009.1 |
